Notably, noradrenaline reduces inflammatory responses and increases the expression of several neurotrophins, including BDNF [28], suggesting the possible use of noradrenaline-based approaches as an alternative or additional therapies in MS. The gene discussed is BDNF; the disease is myeloid sarcoma.